BGB 324

Drug Profile

BGB 324

Alternative Names: BGB-324; R-428

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; Haukeland University Hospital; Merck Sharp & Dohme; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Benzocycloheptenes; Cycloheptanes; Pyridazines; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Malignant melanoma; Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
  • Preclinical Pancreatic cancer

Most Recent Events

  • 26 Jul 2017 Phase-II clinical trials in Breast cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Combination therapy, Inoperable/Unresectable) in USA (PO) (NCT03184558)
  • 08 Jun 2017 Phase-II clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy, Second-line therapy or greater) in Spain (PO) (EudraCT2016-003608-30)
  • 08 Jun 2017 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease) in Spain (PO) (EudraCT2016-003609-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top